Injection

Approx. Rs 17,000 / BoxGet Latest Price

MOUNJARO 2.5MG (TIRZEPATIDE) KWIKPEN is an innovative, once-weekly injectable treatment used primarily for type 2 diabetes management. It helps improve blood sugar levels and supports significant weight reduction. Its dual-action formula sets it apart in modern metabolic therapy.

MOUNJARO 2.5MG (TIRZEPATIDE) KWIKPEN is a GLP-1 and GIP receptor agonist used for glycemic control in adults with type 2 diabetes. Its unique mechanism targets two key hormone pathways to help regulate insulin, reduce appetite, and promote weight loss. The pre-filled KwikPen ensures easy, accurate, and convenient self-injection. Each pen contains a single 2.5mg dose of tirzepatide and is designed for once-weekly use under medical guidance.

1. Wash your hands and inspect the pen before use.

2. Select an injection site (abdomen, thigh, or upper arm).

3. Clean the site with alcohol.

4. Inject the dose once weekly, on the same day each week.

5. Dispose of the pen safely after use.

Always follow your healthcare provider’s dosing schedule.

• Blood Sugar Control: Helps reduce HbA1c levels effectively in type 2 diabetes patients.

• Weight Management: Shown to significantly support weight loss through appetite regulation.

• Cardiometabolic Health: May improve overall cardiovascular risk markers.

• Dual Hormonal Action: Unique dual-incretin therapy (GLP-1 & GIP) for superior outcomes.

• User-Friendly Delivery: Pre-filled, ready-to-use pen for hassle-free self-administration.

MOUNJARO 2.5MG (TIRZEPATIDE) mimics two natural gut hormones—GLP-1 and GIP. These hormones increase insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite. This dual-hormone targeting enhances glucose control and encourages weight loss more effectively than single-action GLP-1 medications.

While primarily used for type 2 diabetes, MOUNJARO 2.5MG is being researched and used off-label for:

• Obesity in non-diabetics

• Polycystic Ovary Syndrome (PCOS)

• Prediabetes management

• Metabolic syndrome

These uses should be under specialist guidance.

• Always take the medication at the same time weekly.

• Do not skip doses; set a reminder if needed.

• Consult your healthcare provider before adjusting the dose.

• Monitor your blood sugar regularly.

• Combine with a balanced diet and physical activity for best results.

1. Not for Type 1 Diabetes – This medication is not suitable for patients with type 1 diabetes or diabetic ketoacidosis.

2. Avoid During Pregnancy – Safety in pregnancy has not been established; consult your doctor if you are pregnant or planning.

3. Thyroid Concerns – Use cautiously if you have a personal or family history of thyroid tumors or medullary thyroid carcinoma.

Q1: What is MOUNJARO 2.5MG used for?
A: It is primarily used to improve blood sugar control in adults with type 2 diabetes and to support weight loss.

Q2: Is MOUNJARO suitable for non-diabetics?
A: While it is approved for diabetes, doctors may prescribe it off-label for obesity or metabolic disorders.

Q3: How often should I take MOUNJARO?
A: It is administered once a week, on the same day each week.

Approx. Rs 26,500 / BoxGet Latest Price

MOUNJARO 7.5MG (TIRZEPATIDE) KWIKPEN is an innovative, once-weekly injectable treatment used primarily for type 2 diabetes management. It helps improve blood sugar levels and supports significant weight reduction. Its dual-action formula sets it apart in modern metabolic therapy.

MOUNJARO 7.5MG (TIRZEPATIDE) KWIKPEN is a GLP-1 and GIP receptor agonist used for glycemic control in adults with type 2 diabetes. Its unique mechanism targets two key hormone pathways to help regulate insulin, reduce appetite, and promote weight loss. The pre-filled KwikPen ensures easy, accurate, and convenient self-injection. Each pen contains a single 7.5mg dose of tirzepatide and is designed for once-weekly use under medical guidance.

1. Wash your hands and inspect the pen before use.

2. Select an injection site (abdomen, thigh, or upper arm).

3. Clean the site with alcohol.

4. Inject the dose once weekly, on the same day each week.

5. Dispose of the pen safely after use.

Always follow your healthcare provider’s dosing schedule.

• Blood Sugar Control: Helps reduce HbA1c levels effectively in type 2 diabetes patients.

• Weight Management: Shown to significantly support weight loss through appetite regulation.

• Cardiometabolic Health: May improve overall cardiovascular risk markers.

• Dual Hormonal Action: Unique dual-incretin therapy (GLP-1 & GIP) for superior outcomes.

• User-Friendly Delivery: Pre-filled, ready-to-use pen for hassle-free self-administration.

MOUNJARO 7.5MG (TIRZEPATIDE) mimics two natural gut hormones—GLP-1 and GIP. These hormones increase insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite. This dual-hormone targeting enhances glucose control and encourages weight loss more effectively than single-action GLP-1 medications.

While primarily used for type 2 diabetes, MOUNJARO 7.5MG is being researched and used off-label for:

• Obesity in non-diabetics

• Polycystic Ovary Syndrome (PCOS)

• Prediabetes management

• Metabolic syndrome

These uses should be under specialist guidance.

• Always take the medication at the same time weekly.

• Do not skip doses; set a reminder if needed.

• Consult your healthcare provider before adjusting the dose.

• Monitor your blood sugar regularly.

• Combine with a balanced diet and physical activity for best results.

1. Not for Type 1 Diabetes – This medication is not suitable for patients with type 1 diabetes or diabetic ketoacidosis.

2. Avoid During Pregnancy – Safety in pregnancy has not been established; consult your doctor if you are pregnant or planning.

3. Thyroid Concerns – Use cautiously if you have a personal or family history of thyroid tumors or medullary thyroid carcinoma.

Q1: What is MOUNJARO 7.5MG used for?
A: It is primarily used to improve blood sugar control in adults with type 2 diabetes and to support weight loss.

Q2: Is MOUNJARO suitable for non-diabetics?
A: While it is approved for diabetes, doctors may prescribe it off-label for obesity or metabolic disorders.

Q3: How often should I take MOUNJARO?
A: It is administered once a week, on the same day each week.

Product Price :Get Latest Price

Amikacin Sulphate 500mg Injection works by stopping the growth of bacteria. It is given as a drip (intravenous infusion) or as an injection directly into a vein or a muscle under the supervision of a doctor and should not be self-administered. It should be used regularly at evenly spaced time intervals as prescribed by your doctor. Do not skip any doses and finish the full course of treatment even if you feel better. Stopping the medicine too early may lead to the infection returning or worsening.

Common side effects of this medicine include injection site reactions, kidney problems, and hearing problems. Consult your doctor if any of these side effects persist or if your condition does not improve despite treatment.

Some patients receiving high doses may develop balance disorder (loss of balance), kidney damage, and hearing loss. Therefore, please follow all the instructions given by your doctor while using this medicine. Your doctor may also monitor you with regular kidney function tests, hearing tests, and urine tests during treatment. This medication is not recommended for use during pregnancy. Inform your doctor if you are pregnant, planning to conceive, or breastfeeding.

Additional Information:

Product Price :Get Latest Price

Amixis 500mg Injection works by stopping the growth of bacteria. It is given as a drip (intravenous infusion) or as an injection directly into a vein or a muscle under the supervision of a doctor and should not be self-administered. It should be used regularly at evenly spaced time intervals as prescribed by your doctor. Do not skip any doses and finish the full course of treatment even if you feel better. Stopping the medicine too early may lead to the infection returning or worsening.

Common side effects of this medicine include injection site reactions, kidney problems, and hearing problems. Consult your doctor if any of these side effects persist or if your condition does not improve despite treatment.

Some patients receiving high doses may develop balance disorder (loss of balance), kidney damage, and hearing loss. Therefore, please follow all the instructions given by your doctor while using this medicine. Your doctor may also monitor you with regular kidney function tests, hearing tests, and urine tests during treatment. This medication is not recommended for use during pregnancy. Inform your doctor if you are pregnant, planning to conceive, or breastfeeding.

Additional Information: